Search

The article considers the issues of the complex therapy for recurrent miscarriage, including in addition to hormonal support, correction of hypercoagulation and thrompbophilic changes of hemostasis, that are often associated with the chronic viral infection. The study of effectiveness of sodium enoxaparine use as part of the complex therapy aimed to prolong the pregnancy in the first trimester, subcutaneous injections of sodium enoxaparine compared to the peroral use of dipyridamol. The hemostasiogram changes and therapeutic outcome were analyzed in this cohort of patients.

Objective: to make analysis of isolated deterioration of blood flow in the pool of uterine arteries in low-risk pregnancy after 18-week gestation, to detect connection of blood flow deterioration with infection processes of different location in the organism of pregnant women.Methods. Doppler screening research was made as well as analysis of spectrograms of uteroplacental and fetal blood flow of 357 pregnant women.Results. Low-risk pregnancy was accompanied by high frequency of hyperdynamic deterioration in the system of "mother-placenta-fetus" (14%), most frequently was detected the reduction of perfusion data of uteroplacental blood flow (67,9%) with almost absolute dominance (prevalence) of one-sided deterioration; high correlation dependence was revealed between reduction of uteroplacental blood flow and existence of extragenital chronic infection foci (71,4%); asymptomatic bacteriuria and infection-and-inflammatory disease of laryngological organs; causal treatment improved hemodynamic rates, with idiopathic forms of uteroplacental perfusion deterioration, pathogenic treatment is recommended, dipyridamol – 75 mg daily (25 mg three times a day) is a chosen medicine.Conclusion. Isolated one-sided deterioration of uteroplacental blood flow during low-risk pregnancy may be considered as the mark of chronic infection foci in the body of a pregnant woman; well-timed diagnostics and causal treatment allow to avoid progressive deterioration of hemodynamic rate.

Fused pyrimidine scaffold is present in several US FDA-approved drugs for various therapeutic indications. Drug repurposing (or drug repositioning) involves the analysis of existing clinically approved drugs for new therapeutic indications. Phosphoinositide-3-kinase (PI3K), via the regulatory PI3K pathway, is involved in cell growth, proliferation, differentiation, survival, and angiogenesis. It is also considered a target in anticancer drug development as it promotes the growth of cancerous cells and increases resistance to anticancer therapy. The present work employed computational techniques like molecular docking, MMGBSA analysis, and molecular dynamics simulations to explore the PI3K inhibition by FDA-approved drugs with fused pyrimidine scaffold. The work identifies Lapatinib as a pan-class I PI3K inhibitor and Dipyridamole as an γ isoform-specific PI3K inhibitor and is reported here.Communicated by Ramaswamy H. Sarma.

There is a great number of coronary patients to whom traditional methods of myocardium revascularization are not indicated. Addition of dipyridamol to traditional antianginal treatment promotes improvement of clinical features of the disease and decreased functional class of angina in coronary patients. The usage of dipyridamol for 3 months was accompanied by increased physical stress tolerance threshold, increased time of physical stress, decreased asynergy areas on echo ate peak stress, suggesting possible angiogenesis in myocardium hypoperfusion areas in the region of stenotic coronary artery.

We have practiced courses of treatment with dipyridamol (Curantil, Berlin-Chemie), 25 to 225 mg daily, 1-3 months long, in 55 patients with congestive heart failure NYHA III-IV class in conjuction with baseline treatment with ACE inhibitors, prolonged nitrates and diuretics. Treatment efficacy was controlled by thromboelastography, ADP-induced platelet aggregation and bifunctional daily BP and ECG monitoring. A dose-dependent and modulating antiaggregating effect of dipyridamol has been shown in the study. The usage of 225 mg Curantil daily (75 mg 3 times a day) resulted in an antiaggregating action in the first day, however, it was characterized by a higher risk of hypotension with concomitant baseline vasodilating therapy. Considerable antiaggregating effect of 75 mg Curnatil daily (25 mg 3 times a day) and 50-25 mg daily developed by the end of the first and, respectively, second week of treatment; the risk of arterial hypotension was non-significant. We conclude that for long-term prevention in patients with CHF administration of Curantil 75-25 mg daily is preferable. Determining individual sensitivity to the chosen dose (by BP dynamics) is rational before initiating the treatment.

Introduction: Cerebrovascular reserve is one of the impor-tant parameters for implementation and monitoring of neuro-surgical intervention success in patients after ischemic stroke, transient ischemic attack, or to indicate the type of dementia. Aim: The aim of this paper is to inform about the implemen-tation of dipyridamole vasodilator test as a possible alterna-tive pharmacological stress, the incidence of side effects, the obtained results and its advantages and weaknesses. Material and Methods: A retrospective analysis of 20 pa-tients (8 women and 12 men in the age range 37 to 78 years), 6 after transient ischemic attack, 14 after ischemic stroke, were examined during two years. Patients were scanned with gamma camera Infinia Hawkeye using fan beam collimators with SPECT technique, at first in a standard way under basal conditions and afterwards within 1-13 days after dipyridamole pharmacologic stress (by iv infusion at a dose of 0.84 mg/kg into 50 ml of F1/1 within 4 min) followed by i.v. injection of 99mTc-HMPAO in the 10th minute. Side effects of dipyridamole was recorded; Syntophyllin was used as an antidote. Differen-ces in basal and post-stress studies were evaluated visually and semiquantitatively using NeuroGamTMSegami and Statis-tical Parametric Mapping. Results: Cerebrovascular reserve was normal in 9 patients (45 %), reduced in 11 patients (55 %). 8 patients (6 men, 2 wo-men) with internal carotid artery occlusion (6 on right, 2 on left) were treated subsequently neurosurgically, 6 (75 %) of these patients were with pathological findings of cerebrovascular reserve, 2 (25 %) had normal cerebrovascular capacity. 12 re-maining patients were treated conservatively, 5 (42 %) of the-se patients had pathological (mild reduce occurrence, compli-cations preoperatively) and 7 (58 %) patients had normal cereb-rovascular reserve. Side effects of dipyridamole (hypotension, cough, chest tight-ness, headache) were recorded in 5 patiens; they decline wi-thin 2-5 minutes. Conclusion: Stress brain perfusion scintigraphy with dipyri-damole administration is the appropriate test to assess vascu-lar brain reserve. It is non-invasive, easily accessible and it contributes to the decision of neurosurgery. [ABSTRACT FROM AUTHOR]

Although arterialovenous fistulae (AVF) is considered to be vital for chronic kidney disease (CKD) patients, but they may cause complications and problems. For instance they may fail soon after their creation. The most important cause of failure in these cases is intrafistula thrombus formation. Whereas anti-platelet drugs are not routinely used after fistulae creation, we conducted this study to determine the effect of these drugs (aspirin and dipyridamol) on the patency of AVFs. From Sep 2003 to Aug 2007, all CKD patients who needed AVF for hemodilysis were included in our study. After fistulae creation, they were randomly divided in 3 groups. The first group was received aspirin and the second one with dipyridamol and the third one was the control group that received placebo. Each group consisted of 130 patients. Exclusion criteria were bleeding tendency, active peptic ulcer disease, pregnancy, lactation, use of anticoagulant and or non steroidal anti-inflammatory drugs, hepatic insufficiency and history of significant side effects from aspirin or dipyridamol. The patency of AVF in the control, aspirin and dipyridamol groups were obtained 69.2%, 70.8% and 75.4% respectively. Although the patency in the aspirin and the dipyridamol group were 1.6% and 6.2% more than the control group, but there was no statistically significant difference between them and placebo (The p-value was 0.892 for the aspirin group and 0.332 for the dipyridamol group). Our study showed that neither the aspirin nor the dipyridamol can be effective on the patency of AVF after 72 h even within six months period. [ABSTRACT FROM AUTHOR]

Copyright of Medizinische Klinik (Urban & Vogel) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Acetylsalicylic acid (ASA) is a strong, irreversible inhibitor of platelet aggregation, but loses this activity following first-pass deacetylation to salicylic acid (SA). In order to compare the bioavailability of unchanged ASA from rapid- and slow-release formulations, the single-dose concentration profiles of ASA and SA were studied in healthy volunteers following intake of two different rapid-release (conventional and effervescent tablets) and three different slow-release (microencapsulated ASA in tablets and in capsules, and enteric-coated tablets) formulations of ASA, and of one slow-release formulation of sodium salicylate. Since anti-platelet therapy with ASA is often combined with dipyridamol, the influence of this drug was also examined. The concentrations of ASA and SA were measured by high-pressure liquid chromatography. While the bioavailability of SA from the 5 ASA formulations was essentially equal and similar to that of the salicylate formulation, the bioavailability and peak concentrations of ASA appeared to be the much greater after rapid-release than after slow-release formulations. Indeed, ASA was only rarely detected in systemic blood following intake of slow-release ASA. Co-administered dipyridamol did not significantly influence the kinetics of ASA or SA. It appears that rapid-release formulations of ASA should be prefered in anti-platelet therapy, either alone or in combination with dipyridamol. [ABSTRACT FROM AUTHOR]

Dipyridamol has in addition to a coronardilatating effect an antithrombotic one too. Moreover it facilitates the release of O from haemoglobin by increase of the concentration of 2,3-diphosphoglycerate in the erythrocytes. Allopurinol causes a potential resynthesis of ATP in the cells by inhibition of the metabolism of uric acid. Both substances therefore seemed to be suitable for a medicamental therapy of the noise-induced cochlear damage. The expected favourable effect of Dipyridamol and Allopurinol on the organ of Corti after sound exposure (RMP-measurement before and after exposure to pure tone 120 dB SPL) however had not been confirmed by experiment on animals (guinea Pig). [ABSTRACT FROM AUTHOR]

Dipyridamole stress is favorable in patients unable to exercise maximally forTl myocardial scintigraphy. Aside from an analysis of uptake defects, proper washout analysis can be limited by heart rate variations when isolated dipyridamole stress is used. Heart rate standardizedTl washout kinetics after a combined dipyridamole and submaximal exercise stress protocol (CDSE), feasible in elderly patients as well as in patients with peripheral artery disease, were therefore studied to investigate theTl washout after CDSE in differently defined patient groups: Group I comprised 19 patients with documented heart disease and angiographically excluded coronary artery disease (CAD); group II contained 17 patients with a very low likelihood of CAD determined by both normal exercise radionuclide ventriculography and normalTl uptake. Group III comprised 56 patients with a 50% pretest likelihood of CAD but normalTl uptake. Mean washout values were nearly identical in all groups. Despite similar uptake patterns, however, washout standardized by CDSE was significantly lower than the normal washout values after maximal treadmill exercise. Thus an obviously lowerTl washout after CDSE than after maximal treadmill exercise must be considered if washout analysis criteria after dipyridamole are applied to evaluate ischemic heart disease. Nevertheless, heart rate elevation achieved by additional submaximal exercise stress seems necessary, adequate and clinically safe for standardisation of washout analysis in dipyridamoleTl scintigraphy. [ABSTRACT FROM AUTHOR]

In isolated guinea pig hearts epicardial perfusion was estimated by analysis of the transit profile of different fluorescence indicators. Several coronary dilating agents were tested with regard to their influence on local perfusion kinetics revealing distinct patterns of microcirculatory drug action. [ABSTRACT FROM AUTHOR]

Copyright of Medizinische Klinik (Urban & Vogel) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Pflüger's Archiv Für Die Gesamte Physiologie Des Menschen Und Der Tiere is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

10-10 M Dipyridamole, which is used for coronary dilation' lowers the permeability of erythrocytes of guinea pigs to adenosine and inosine. For inhibition of the adenosine deaminase, however, concentrations of 10 M are necessary. There is a difference of 10-10 between the concentration of dipyridamole which inhibits the adenosine deaminase and the concentration which decreases the permeability of erythrocytes to adenosine or inosine. Therefore the inhibition of uptake into the cells should be more important for the pharmacological effects than the inhibition of the adenosine deaminase. The unchanged deamination of adenosine by a concentration of 10 M Di-pyridamole, which inhibits the uptake of adenosine into the cells completely, indicates, that adenosine is deaminated on the outer surface of the cell membrane. [ABSTRACT FROM AUTHOR]

Copyright of Pflügers Archiv: European Journal of Physiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Der Nervenarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The use of antithrombotic drugs (ATD) is necessary in the treatment and prevention of thrombosis. The correction of risk factors of ischemic stroke (IS) and transitory ischemic attacks (TIA) is important as well. The drugs inhibiting the activation and aggregation of thrombocytes allow to decrease the number of myocardial infarctions by 35%, stroke by 25% and mortality from cardiovascular causes by 15%. Currently, the clinical efficacy of acetylsalicylic acid (ASA), thienopyridines (ticlopidine, clopidogrel), dipyridamole or the combination of dipyridamole and ASA as well as glycoprotein antagonists IIb-IIIa for intravenous introduction have been confirmed. A review of experimental and clinical studies confirming the efficacy of dipyridamole in the treatment of acute stage of stroke and primary and secondary prevention of II is presented.